Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,010 across all filing types
Latest filing 2025-11-21 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
外部信息使用人管理制度（2025年修订）
Regulatory Filings Classification · 95% confidence The document is titled as an internal management system for external information users of 康芝药业股份有限公司 (Kangzhi Pharmaceutical Co., Ltd.), specifically focusing on the management of information disclosure, confidentiality, and compliance with relevant laws and regulations. It outlines procedures and responsibilities related to the handling of periodic reports, interim reports, and major events, but it does not contain any financial data, financial statements, or report results. It is a governance or compliance policy document rather than a financial report or announcement. The document length is 2533 characters, which is relatively short and more consistent with a regulatory or governance policy document. There is no indication that this is an announcement of a report publication or a certification. Therefore, the best fitting category is Regulatory Filings (RNS), as it is a compliance-related document that does not fit into other specific categories.
2025-11-21 Chinese
内部审计工作制度（2025年修订）
Audit Report / Information Classification · 95% confidence The document is titled '内部审计工作制度' (Internal Audit Work System) for 康芝药业股份有限公司, revised in 2025. It details the internal audit policies, responsibilities, procedures, quality control, and penalties related to the company's internal audit function. It references regulatory frameworks and internal governance but does not contain financial statements, financial results, or external audit opinions. It is a governance and procedural document focused on internal audit standards and controls rather than a standalone audit report or annual report. Therefore, it fits best under 'Audit Report / Information (AR)' as it relates to internal audit work and internal control evaluation, but is not a full annual report or external audit report. The document length (6611 characters) and content confirm it is a substantive internal audit policy document, not a brief announcement or certification. Hence, the classification is AR with high confidence. FY 2025
2025-11-21 Chinese
独立董事提名人声明与承诺（方灿辉）
Regulatory Filings Classification · 95% confidence The document is a formal statement and declaration by the nominating party (the company's board) regarding the nomination of an independent director candidate for the company's board. It includes detailed compliance affirmations about the nominee's qualifications, independence, and adherence to relevant laws and regulations. There is no financial data, no report of financial performance, no voting results, no management changes announcement, and no earnings or capital update. The document is a regulatory announcement related to board nomination compliance and disclosures. It fits best under Regulatory Filings (RNS) as it is a compliance and disclosure document that does not fit other specific categories.
2025-11-21 Chinese
独立董事候选人声明与承诺（郑欢雪）
Board/Management Information Classification · 95% confidence The document is a formal declaration and commitment statement by an independent director candidate for a company's board. It includes detailed attestations about the candidate's qualifications, independence, and compliance with relevant laws and regulations. There are no financial statements, earnings data, or report summaries. The content is focused on board/management information, specifically about a director candidate's qualifications and commitments. This fits the category of Board/Management Information (MANG). The document length is 4583 characters, which is sufficient for a detailed declaration rather than a brief announcement. Therefore, the appropriate classification is MANG with high confidence.
2025-11-21 Chinese
独立董事候选人声明与承诺（唐林艳）
Board/Management Information Classification · 95% confidence The document is a formal declaration and commitment statement by an independent director candidate for a company's board. It includes detailed attestations about the candidate's qualifications, independence, compliance with relevant laws and regulations, and commitments to fulfill the duties of an independent director. There are no financial statements, earnings data, or report summaries. The document is not an announcement of a report publication but a regulatory compliance statement related to board management and governance. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or appointments in the company's board of directors or senior management.
2025-11-21 Chinese
关于公司股价异动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding abnormal stock price fluctuations of the company 康芝药业股份有限公司 (Kangzhi Pharmaceutical Co., Ltd.). It details the stock price movements over specific dates, the company's investigation into the cause, confirmation of no undisclosed material information, and risk warnings to investors. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document serves as a regulatory disclosure about stock price abnormality and compliance with stock exchange rules, rather than a financial report or earnings release. It fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about stock price movements and company disclosures without substantive financial data or report content.
2025-11-18 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.